Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  All
Drug:  Gleevec
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
Binimetinib and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-162, NCI-2013-02281, NCT01991379
BGJ398 and Imatinib Mesylate in Treating Patients with Untreated Advanced Gastrointestinal Stromal Tumor
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-140, NCI-2014-02117, NCT02257541
Recombinant Interferon Alpha-2a and Sargramostim or Vaccine Therapy in Treating Patients with Chronic Phase Chronic Myelogenous Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J05121, NCI-2011-00392, CDR0000492005, JHOC-J05121, NA_00001887, NCT00363649
Open Label, Randomized Phase 2b Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who do Not Have Favorable Imatinib Response (DASCERN)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CA180-399, NCI-2012-02781, 2011-006181-41, NCT01593254
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Phase: Phase I
Type: Treatment
Age: 15 and over
Trial IDs: 2012-0784, NCI-2013-00030, NCT01738139
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Phase: No phase specified
Type: Health services research, Natural history/Epidemiology
Age: 18 and over
Trial IDs: CA180-330, NCI-2013-02015, NCT01244750
Start Over